Fiche publication
Date publication
mars 2016
Journal
Presse medicale (Paris, France : 1983)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HAFFEN Emmanuel
Tous les auteurs :
Saba G, Nieto I, Bation R, Allaïli N, Bennabi D, Moliere F, Richieri R, Holtzmann J, Bubrovszky M, Camus V, Charpeaud T, Courtet P, Courvoisier P, Haesebaert F, Doumy O, El-Hage W, Garnier M, d'Amato T, Bougerol T, Lançon C, Haffen E, Llorca PM, Vaiva G, Bellivier F, Leboyer M, Aouizerate B
Lien Pubmed
Résumé
Non-selective and irreversible MAOI have become as third or fourth-line strategy for the management of treatment-resistant depression. Non-selective and irreversible MAOI requires careful monitoring of drug interactions and dietary restrictions. Nutritional supplements such as omega-3 have been found to produce beneficial effects in the management of treatment-resistant depression when administered in combination with the ongoing antidepressant treatment. The glutamate antagonist ketamine has been found to produce beneficial effects in the management of treatment-resistant depression while administered alone. Dopamine and/or norepinephrine agonists, such as methylphenidate, modafinil or pramipexole, have been found to produce beneficial effects in the management of treatment-resistant depression when administered in combination with the ongoing antidepressant treatment.
Mots clés
Adrenergic alpha-Agonists, therapeutic use, Antidepressive Agents, pharmacokinetics, Central Nervous System Stimulants, therapeutic use, Depressive Disorder, drug therapy, Dietary Supplements, Dopamine Agonists, therapeutic use, Double-Blind Method, Drug Interactions, Drug Resistance, Drug Therapy, Combination, Excitatory Amino Acid Antagonists, therapeutic use, Fatty Acids, Omega-3, therapeutic use, Folic Acid, therapeutic use, Food-Drug Interactions, Humans, Ketamine, therapeutic use, Monoamine Oxidase Inhibitors, pharmacokinetics, Randomized Controlled Trials as Topic, S-Adenosylmethionine, therapeutic use
Référence
Presse Med. 2016 Mar;45(3):350-9
